Jessica R Zolton1, Toral P Parikh2, Dennis D Hickstein3, Steven M Holland4, Micah J Hill2, Alan H DeCherney2, Erin F Wolff5. 1. Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 10 CRC, Room 1E-3140, 10 Center Drive, MSC 1109, Bethesda, MD, 20892, USA. Jessica.zolton@nih.gov. 2. Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 10 CRC, Room 1E-3140, 10 Center Drive, MSC 1109, Bethesda, MD, 20892, USA. 3. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 4. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 5. Pelex, 931 Douglass Drive, McLean, VA, 22101, USA.
Abstract
PURPOSE: To describe controlled ovarian stimulation (COS) in a population of women with GATA2 deficiency, a genetic bone marrow failure syndrome, prior to allogeneic hematopoietic stem cell transplant METHODS: This is a retrospective case series of nine women with GATA2 deficiency who underwent oocyte preservation at a research institution. Main outcomes measured include baseline fertility characteristics ((antimullerian hormone (AMH) and day 3 follicle-stimulating hormone (FSH) and estradiol (E2)) and total doses of FSH and human menopausal gonadotropins (HMG), E2 on day of trigger, and total number of metaphase II oocytes retrieved. RESULTS: The mean age was 24 years [16-32], mean AMH was 5.2 ng/mL [0.7-10], and day 3 mean FSH was 5.1 U/L [0.7-8.1], and E2 was 31.5 pg/mL [< 5-45]. The mean dose of FSH was 1774 IU [675-4035], and HMG was 1412 IU [375-2925] with a mean E2 of 2267 pg/mL [60.7-4030] on day of trigger. The mean total of metaphase II oocytes was 7.7 [0-15]. One patient was diagnosed with a deep vein thrombosis (DVT) with pulmonary embolism (PE) during COS. CONCLUSION: This study is the first to analyze the outcomes of COS in women with GATA2 deficiency. The response to ovarian stimulation suggests that oocyte cryopreservation should be considered prior to gonadotoxic therapy. However, due to the risk of potentially life-threatening complications, it is prudent that patients are properly counseled of the risks and are evaluated by a multi-disciplinary medical team prior to COS.
PURPOSE: To describe controlled ovarian stimulation (COS) in a population of women with GATA2 deficiency, a genetic bone marrow failure syndrome, prior to allogeneic hematopoietic stem cell transplant METHODS: This is a retrospective case series of nine women with GATA2 deficiency who underwent oocyte preservation at a research institution. Main outcomes measured include baseline fertility characteristics ((antimullerian hormone (AMH) and day 3 follicle-stimulating hormone (FSH) and estradiol (E2)) and total doses of FSH and human menopausal gonadotropins (HMG), E2 on day of trigger, and total number of metaphase II oocytes retrieved. RESULTS: The mean age was 24 years [16-32], mean AMH was 5.2 ng/mL [0.7-10], and day 3 mean FSH was 5.1 U/L [0.7-8.1], and E2 was 31.5 pg/mL [< 5-45]. The mean dose of FSH was 1774 IU [675-4035], and HMG was 1412 IU [375-2925] with a mean E2 of 2267 pg/mL [60.7-4030] on day of trigger. The mean total of metaphase II oocytes was 7.7 [0-15]. One patient was diagnosed with a deep vein thrombosis (DVT) with pulmonary embolism (PE) during COS. CONCLUSION: This study is the first to analyze the outcomes of COS in women with GATA2 deficiency. The response to ovarian stimulation suggests that oocyte cryopreservation should be considered prior to gonadotoxic therapy. However, due to the risk of potentially life-threatening complications, it is prudent that patients are properly counseled of the risks and are evaluated by a multi-disciplinary medical team prior to COS.
Authors: Jennifer Cuellar-Rodriguez; Juan Gea-Banacloche; Alexandra F Freeman; Amy P Hsu; Christa S Zerbe; Katherine R Calvo; Jennifer Wilder; Roger Kurlander; Kenneth N Olivier; Steven M Holland; Dennis D Hickstein Journal: Blood Date: 2011-08-03 Impact factor: 22.113
Authors: S Joshi; B N Savani; E J Chow; M H Gilleece; J Halter; D A Jacobsohn; J Pidala; G P Quinn; J-Y Cahn; A A Jakubowski; N R Kamani; H M Lazarus; J D Rizzo; H C Schouten; G Socie; P Stratton; M L Sorror; A B Warwick; J R Wingard; A W Loren; N S Majhail Journal: Bone Marrow Transplant Date: 2014-01-13 Impact factor: 5.483
Authors: Bruce S Shapiro; Said T Daneshmand; Forest C Garner; Martha Aguirre; Cynthia Hudson; Shyni Thomas Journal: Fertil Steril Date: 2009-03-17 Impact factor: 7.329
Authors: Michael A Charles; Thomas L Saunders; William M Wood; Kailey Owens; A F Parlow; Sally A Camper; E C Ridgway; David F Gordon Journal: Mol Endocrinol Date: 2006-03-16
Authors: Amy P Hsu; Kirby D Johnson; E Liana Falcone; Rajendran Sanalkumar; Lauren Sanchez; Dennis D Hickstein; Jennifer Cuellar-Rodriguez; Jacob E Lemieux; Christa S Zerbe; Emery H Bresnick; Steven M Holland Journal: Blood Date: 2013-03-15 Impact factor: 22.113
Authors: Donald C Vinh; Smita Y Patel; Gulbu Uzel; Victoria L Anderson; Alexandra F Freeman; Kenneth N Olivier; Christine Spalding; Stephen Hughes; Stefania Pittaluga; Mark Raffeld; Lynn R Sorbara; Houda Z Elloumi; Douglas B Kuhns; Maria L Turner; Edward W Cowen; Danielle Fink; Debra Long-Priel; Amy P Hsu; Li Ding; Michelle L Paulson; Adeline R Whitney; Elizabeth P Sampaio; David M Frucht; Frank R DeLeo; Steven M Holland Journal: Blood Date: 2009-12-29 Impact factor: 22.113
Authors: Amanda Kohlmeier; Christia Angela M Sison; Bahar D Yilmaz; John S Coon V; Matthew T Dyson; Serdar E Bulun Journal: Endocrinology Date: 2020-06-01 Impact factor: 4.736
Authors: Jae Jun Shin; Young Min Choi; Jong Kwan Jun; Kyung-Hun Lee; Tae-Yong Kim; Wonshik Han; Seock-Ah Im Journal: J Breast Cancer Date: 2020-05-11 Impact factor: 3.588